PRODUCT MONOGRAPH

[Pr]BUSPIRONE

(Buspirone Hydrochloride)

Tablets

USP

Anxiolytic

Sanis Health Inc.
333 Champlain Street, Suite 102
Dieppe, New Brunswick
E1A 1P2

www.sanis.com

Date of Preparation:
October 26, 2015

Control Number: 188245

PRODUCT MONOGRAPH

^{Pr}BUSPIRONE

(Buspirone Hydrochloride)

Tablets

USP

THERAPEUTIC CLASSIFICATION

Anxiolytic

ACTION AND CLINICAL PHARMACOLOGY

BUSPIRONE (buspirone hydrochloride) is a psychotropic drug with anxiolytic properties which belongs chemically to the class of compounds known as the azaspirodecanediones.

Buspirone shares some of the properties of the benzodiazepines and the neuroleptics, as well as demonstrating other pharmacological action. Buspirone attenuates punishment suppressed behaviour in animals and it exerts a taming effect, but it is devoid of anticonvulsant and muscle relaxant properties and it does not bind to the benzodiazepine/GABA receptor complex. Buspirone affects a variety of dopamine mediated biochemical and behavioural events are affected by buspirone but it is free of cataleptic activity. Buspirone has an affinity for brain D_2-dopamine receptors, where it acts as an antagonist and agonist, and for the 5-HT_{1A} receptors, where it acts as an agonist. Buspirone does not block the neuronal reuptake of monoamines is not blocked by buspirone and, on chronic administration, it does not lead to changes in receptor density in the models investigated. However, the mechanism of action of buspirone remains to

be fully elucidated.

Buspirone is rapidly absorbed in man and undergoes extensive first pass metabolism. Following oral administration, low peak plasma levels of unchanged drug, of 1 to 6 ng/mL were observed 40 to 90 minutes after a single 20 mg dose. In a number of studies in healthy volunteers, the mean half-life of buspirone ranged from 2 to 3 hours up to approximately 11 hours with considerable variation in individual values. Multiple dose studies suggest that steady state plasma levels are usually achieved within a few days. Buspirone is metabolized primarily by oxidation, producing several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP). Peak plasma levels of 1-PP have been found to be higher than those of its parent drug, buspirone, and its half-life to be approximately double that of unchanged buspirone. In a single dose study with ^{14}C labelled buspirone, 29 to 63% of the dose was excreted in the urine within 24 hours, primarily as metabolites, while fecal excretion accounted for 18 to 38% of the dose. In man, approximately 95% of buspirone is plasma protein bound, but other highly bound drugs, e.g., phenytoin, propranolol and warfarin, are not displaced by buspirone from plasma protein *in vitro*. However, *in vitro* binding studies show that buspirone does displace digoxin.

The effects of food upon the bioavailability of buspirone was studied in eight subjects. The area under the plasma concentration curve (AUC) and peak concentration (C_{max}) of unchanged buspirone increased by 84% and 116%, respectively, when the drug was administered with food, but the total amount of buspirone immunoreactive material did not change. The significance of this finding is not known, but it could indicate that food may decrease the pre-systemic clearance

of buspirone.

Buspirone had no effect on hepatic microsomal enzyme activity when administered to rats for 5 days. In man the effect of buspirone on drug metabolism or concomitant drug disposition has not been studied. The pharmacokinetics of buspirone in patients with hepatic or renal dysfunction, and in the elderly, has not been clearly established.

A two-way, double-blind, single-dose, comparative, randomized, bioavailability study was conducted in forty healthy male volunteers between two 10 mg (4 X 10 mg) buspirone tablet products under fasting conditions. The pharmacokinetic plasma data calculated for both - BUSPIRONE and Buspar® tablets are tabulated below:

Pharmacokinetic Indices for Buspirone Under Fasting Conditions:

	Geometric mean Arithmetic mean (C.V.)		
	BUSPIRONE 4 x 10 mg	Buspar®** 4 x 10 mg	Percentage of Buspar®
AUC_T (ng•h/mL)	7.10 9.73 (89)	6.42 8.47 (90)	110
AUC_I (ng•h/mL)	7.69 10.2 (85)	7.17 8.99 (84)	107
C_{max} (ng/mL)	2.53 3.41 (84)	2.25 2.97 (91)	112
T_{max}* (h)	0.87 (72)	1.10 (84)	-
$T_{1/2}$*	2.39 (32)	2.40 (42)	-

(h)			

*****For the T_{max} and $T_{1/2}$ parameters these are the arithmetic means (standard deviation).
******Buspar® manufactured by Bristol Myers Squibb Inc., Montreal, Canada

INDICATIONS AND CLINICAL USE

BUSPIRONE (buspirone hydrochloride) is indicated in the short term symptomatic relief of excessive anxiety in patients with generalized anxiety disorder (psychoneurotic disorder).

Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of BUSPIRONE in long-term use (i.e. more than 4 weeks) has not been evaluated in controlled clinical trials.

Eight three-way, short term, controlled clinical trials involving buspirone, diazepam and placebo are considered central to the evaluation of buspirone as an anxiolytic agent. In four of the eight clinical trials, buspirone demonstrated a significant difference from placebo in several clinical trials. In the other four trials, there was no significant difference between buspirone and placebo, but a significantly greater improvement was observed in two of these trials with diazepam than with placebo. The adverse reaction profiles of buspirone and diazepam in these clinical trials were, however, different.

CONTRAINDICATIONS

BUSPIRONE (buspirone hydrochloride) is contraindicated in patients which are hypersensitive

to buspirone hydrochloride.

BUSPIRONE is also contraindicated in patients with severe hepatic or severe renal impairment.

WARNINGS

MAO Inhibitors

The occurrence of elevated blood pressure in patients receiving both buspirone hydrochloride and a monoamine oxidase inhibitor (MAOI) has been reported. Therefore, it is recommended that buspirone should not be used concomitantly with an MAOI.

Extrapyramidal Symptoms

Since buspirone can bind to central dopaminergic receptors the possibility of acute and chronic changes in dopamine mediated neurological function (e.g., dystonia, pseudo-parkinsonism, akathisia and tardive dyskinesia) should be considered (see Precautions).

Convulsive Disorders

Since the effects of buspirone have not been evaluated in patients with a history of convulsive disorders, the drug is not recommended for use in these patients.

Use of Buspirone in Patients Previously Treated with a Benzodiazepine:

Patients who have previously taken benzodiazepines may be less likely to respond than those who have not. In two clinical studies substitution of buspirone did not ameliorate or prevent withdrawal symptoms in either abrupt or gradual withdrawal from various benzodiazepines following long-term use. Therefore, if it is considered desirable to switch a patient who has been

receiving benzodiazepine therapy to buspirone, the benzodiazepine should first be withdrawn gradually. A drug-free interval is desirable between withdrawal of the benzodiazepine and initiation of buspirone, in order to increase the likelihood of distinguishing between benzodiazepine withdrawal effects and unrelieved anxiety due to possible failure of buspirone in this category of patients.

Benzodiazepine rebound or withdrawal symptoms may occur over varying time periods depending in part on the type of drug and its effective half-life of elimination. These symptoms may appear as any combination of irritability, anxiety, agitation, insomnia, tremor, abdominal cramps, muscle cramps, vomiting, sweating, flu-like symptoms without fever and, occasionally, seizures, and should be treated symptomatically.

Use in Pregnancy and Lactation

The safety of buspirone during pregnancy and lactation has not been established and, therefore, it should not be used in women of childbearing potential or nursing mothers, unless, in the opinion of the physician, the potential benefits to the patient outweigh the possible hazards to the fetus. Buspirone and its metabolites are excreted in milk in rats. The extent of excretion in human milk has not yet been determined.

PRECAUTIONS

Effects on Cognitive and Motor Performance

In controlled studies in healthy volunteers single doses of buspirone up to 20 mg had little effect on most tests of cognitive and psychomotor function, although performance on a vigilance task

was impaired in a dose-related manner. The effect of higher single doses of buspirone on psychomotor performance has not been investigated.

Ten (10) mg of buspirone given three times daily for seven days to healthy volunteers resulted in considerable subjective sedation but no significant effect on psychomotor performance (no vigilance tasks were used in this study). It also caused transient dizziness, especially on standing and walking.

Until further evidence is obtained with buspirone, patients should be warned not to operate an automobile or undertake activities requiring mental alertness, judgment and physical coordination, until they are reasonably certain that buspirone does not affect them adversely.

Significant Drug Interactions

In laboratory studies in healthy volunteers, buspirone in doses up to 20 mg did not potentiate the psychomotor impairment produced by relatively modest doses of alcohol. However, decreased contentedness or dysphoria was observed with a combination of alcohol and a 20 mg single dose of buspirone. Since no data are available on concomitant use of higher doses of buspirone and alcohol it is prudent to advise patients to avoid alcohol during buspirone therapy.

Food increased the bioavailability of unchanged buspirone in healthy subjects, possibly due to a reduced first-pass effect.

Concomitant use of monoamine oxidase inhibitors and buspirone have been reported to cause an

increase in blood pressure. Therefore, concomitant use of these medications is not recommended.

In a study in normal volunteers, no interaction of buspirone with amitriptyline was seen. A similar study with buspirone and diazepam showed an increase in the levels of nordiazepam.

In another study in normal volunteers concomitant administration of buspirone and haloperidol resulted in increased serum haloperidol concentrations. The clinical significance of this finding is not clear.

There is one report suggesting that the concomitant use of trazodone and buspirone may have caused 3- to 6-fold elevations in SGPT (ALT) in a few patients. In a similar study attempting to replicate this finding no interactive effect on hepatic transaminases was identified.

Because the effects of concomitant administration of buspirone with most other psychotropic drugs have not been studied, the concomitant use of buspirone with other CNS active drugs should be approached with caution.

In vitro buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins. However there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin. The patient was also chronically receiving phenytoin, phenobarbitol, digoxin and Synthroid®. *In vitro* buspirone may displace less firmly bound drugs like digoxin. The clinical significance of this

property is unknown.

There have been no reports to date of interference of buspirone with commonly employed clinical laboratory tests.

Drug Abuse and Dependence

Although preliminary animal and human investigations suggesting that buspirone may be significantly devoid of potential for producing physical or psychological dependence, only extensive clinical experience with the drug will provide conclusive evidence. Meanwhile, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of buspirone misuse and abuse.

Use in Patients with Impaired Hepatic or Renal Function:

Since it is metabolized by the liver and excreted by the kidneys, buspirone should be used with caution in patients with a history of hepatic or renal impairment. Buspirone is contraindicated in patients with severe hepatic or renal impairment.

Use in Children:

The safety and effectiveness of buspirone in individuals below the age of 18 years have not been established.

Use in the Elderly:

Buspirone has not been systematically evaluated in older patients. Although it would appear

from limited pharmacokinetic and clinical studies that buspirone does not behave differently in the elderly, little is known about the effects of buspirone in this age group at doses above 30mg/day. Therefore it is recommended that buspirone should be used in the elderly at doses not exceeding 30 mg/day for a duration not exceeding 4 weeks.

Neuroendocrine Effects:

Single doses of 30 mg or higher of buspirone resulted in significantly elevated plasma prolactin and growth hormone concentrations in normal volunteers. No effect was seen at lower doses. In another study, no such increases were observed after buspirone was administered in divided doses (10 mg t.i.d.) for 28 days.

Possible Concerns Related to Buspirone's Binding to Dopamine Receptors:

Since buspirone is able to bind to central dopamine receptors, a question has been raised regarding its potential to cause acute and chronic changes in dopamine mediated neurological function (e.g., dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia). Clinical experience in controlled trials has not revealed any significant neuroleptic-like activity; however, a syndrome of restlessness, appearing shortly after initiation of treatment, has been reported in some small fraction of buspirone treated patients. The syndrome may be explained in several ways. For example, buspirone may increase central noradrenergic activity; alternatively, the effect may be attributable to dopaminergic effects (i.e., represent akathisia). Obviously, the question cannot be totally resolved at this time. Generally, long-term sequelae of any drug's use can be identified only after several years of marketing.

ADVERSE REACTIONS

The most common adverse reactions encountered with use of buspirone are dizziness, headache, drowsiness and nausea. During controlled clinical efficacy trials, approximately 10% of 2 200 patients discontinued treatment due to an adverse event.

Adverse reactions reported in approximately 3 000 subjects who participated in pre-marketing trials are listed below by body system. Frequent adverse events are defined as those occurring in at least 1/100 patients. Infrequent adverse events are those occurring in less than 1/100 but at least 1/1 000 patients, while rare events are those occurring in less than 1/1 000 patients.

Adverse reactions reported include the following:

CNS:

Frequent: Dizziness, headache, drowsiness, lightheadedness, insomnia, fatigue, nervousness, decreased concentration, excitement, depression, confusion, nightmares/vivid dreams, anger/hostility.

Infrequent: Depersonalization, noise intolerance, euphoria/feeling high, dissociative reaction, fear, loss of interest, dysphoria, hallucinations, seizures, suicidal thoughts.

Rare: Slurred speech, claustrophobia, cold intolerance, stupor, psychosis.

Neurologic:

Frequent: Paresthesia, weakness, incoordination, tremor, numbness.

Infrequent: Muscle cramps and spasms, rigid/stiff muscles, involuntary movements, akathisia,

slowed reaction time.

Rare: Tingling of limbs, stiff neck, rigidity of jaw, ataxia.

Autonomic:

Frequent: Dry mouth, sweating/clamminess, blurred vision, constipation.

Infrequent: Urinary frequency, retention and burning, flushing.

Cardiovascular:

Frequent: Tachycardia, chest pain, palpitations.

Infrequent: Syncope, hypotension, hypertension.

Rare: Congestive heart failure, cerebrovascular accident, myocardial infarction, cardiomyopathy, bradycardia, EKG change.

Gastrointestinal:

Frequent: Nausea, G.I. distress, diarrhea, vomiting.

Infrequent: Flatulence, increased appetite, anorexia, hypersalivation, rectal bleeding, irritable colon.

Rare: Burning tongue.

Respiratory:

Frequent: Nasal congestion.

Infrequent: Shortness of breath, chest congestion, hyperventilation.

Rare: Epistaxis.

Endocrine:

Infrequent: Decreased and increased libido, weight gain, weight loss, menstrual irregularity/breakthrough bleeding.

Rare: Delayed ejaculation, impotence, galactorrhea, amenorrhea, thyroid abnormality.

Allergic or Toxic:

Frequent: Skin rash, sore throat.

Infrequent: Edema/facial edema, pruritus, chills/fever.

Rare: Photophobia, erythema, flu-like symptoms.

Clinical Laboratory:

Infrequent: Increases in liver enzymes.

Rare: Eosinophilia, leukopenia, thrombocytopenia.

Miscellaneous:

Frequent: Tinnitus, muscle aches/pains.

Infrequent: Redness/itching of eyes, altered taste/smell, roaring sensation in head, malaise, easy bruising, dry skin, arthralgia, blisters, hair loss.

Rare: Acne, thinning of nails, sore eyes, inner ear abnormality, pressure on eyes, nocturia, enuresis, hiccups, voice loss, alcohol abuse.

Post Introduction Clinical Experience

Post-marketing experience in the United States has shown a similar adverse experience profile to that reported above. Additional reports have included rare occurrences of allergic reaction, cogwheel rigidity, dystonic reaction, ecchymosis, emotional lability and tunnel vision. Because of the uncontrolled nature of these spontaneous reports, a casual relationship to buspirone treatment has not been determined.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Symptoms: In clinical pharmacology trials, buspirone hydrochloride up to 400 mg/day was administered to healthy male volunteers. As this dose was approached, the following symptoms were observed in descending order of frequency: drowsiness, ataxia, nausea and vomiting, dizziness, clammy feeling, difficulty thinking, feeling "high", "rushing" sensation, gastric distress, headache, itching, miosis, hypotension, tremor, incoordination, insomnia and hallucinations. In a dose ranging study conducted in acute psychotic patients up to 2400 mg/day was administered. Dizziness, nausea and vomiting were the most common adverse effects. One patient developed extrapyramidal symptoms at 600 mg/day.

Treatment: There is no specific antidote for buspirone. Management should therefore, be symptomatic and supportive. Any patient suspected of having taken an overdose should be admitted to a hospital as soon as possible, and the stomach emptied by gastric lavage. Respiration, pulse and blood pressure should be monitored as in all cases of drug overdosage. As with the management of intentional overdosage with any drug, the ingestion of multiple agents should be suspected. In six anuric patients, hemodialysis either had no effect on the pharmacokinetics of buspirone or decreased its clearance.

DOSAGE AND ADMINISTRATION

BUSPIRONE (buspirone hydrochloride) dosage should be individually adjusted, according to tolerance and response.

The recommended initial dose is 5 mg two to three times daily. This may be titrated according to the needs of the patient and the daily dose increased by 5 mg increments every two or three days up to a maximum of 45 mg daily in divided doses. The usual therapeutic dose is 20 to 30 mg daily in two or three divided doses.

Elderly Patients:

Limited pharmacokinetic and clinical data have shown no differences in the effects of buspirone between elderly patients and healthy adult volunteers. However, until more information has accumulated in the elderly, it is recommended that the maximum daily dose should not exceed 30 mg for a duration not exceeding four weeks.

Note: If buspirone is administered to patients with compromised hepatic or renal function careful monitoring will be required together with appropriate dosage adjustment.

PHARMACEUTICAL INFORMATION

DRUG SUBSTANCE

Proper Name: Buspirone Hydrochloride

Chemical Name: 8-Azaspiro[4,5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, monohydrochloride

Structural Formula:



Molecular Formula: C21H31N5O2•HCl Molecular Weight: 421.97

Description: Buspirone hydrochloride is a white to off-white crystalline powder which is freely soluble in water and soluble in methanol. The melting point is 201.5-202.5°C and the pKa_s is 1.22 and 7.32.

COMPOSITION:

Nonmedicinal Ingredients:

Lactose, microcrystalline cellulose, dextrin, sodium starch glycolate, colloidal silicon dioxide and magnesium stearate.

STABILITY AND STORAGE RECOMMENDATIONS: Store tablets in tight, light-resistant containers between 15°C and 30°C.

AVAILABILITY OF DOSAGE FORMS

BUSPIRONE (buspirone hydrochloride) is available as:

10 mg white, barrel-shaped, compressed single-scored tablet engraved ‘N’ on one side and '1 | 0' on the other side containing 10 mg of buspirone hydrochloride.

Supplied: Bottles of 100.

PHARMACOLOGY

Buspirone is a chemically novel agent with a pharmacological profile that is different from those of presently available psychotropic drugs while sharing a number of pharmacologic actions with both the benzodiazepines and the neuroleptics.

Buspirone, like the benzodiazepines, is active in Geller and Vogel conflict tests in which it attenuates punishment suppressed behaviours. In these procedures, doses as low as 0.5 mg/kg s.c. or p.o. were active in cynomolgus monkeys and rats, respectively. However, Ro 15-1788, the benzodiazepine antagonist, had no effect on the buspirone-elicited increased behavioural responding while it antagonized that elicited by the benzodiazepines. At somewhat higher doses, buspirone inhibited footshock-induced fighting behaviour in mice and it exerted a taming effect in aggressive rhesus monkeys. Both effects are characteristic of the benzodiazepines. In contrast, buspirone did not antagonize either chemical (pentylenetetrazol, bicuculline, strychnine, picrotoxin) or electroshock-induced convulsions, possessed minimal sedative activity and exerted minimal muscle relaxant activity.

Buspirone, like neuroleptics, decreased conditioned avoidance behaviour, with the minimal effective dose being approximately 1 mg/kg. At somewhat higher doses, buspirone protected against amphetamine-induced toxicity in aggregated mice and antagonized apomorphine-induced emesis in dogs. Intravenous buspirone (1.25 μg/kg) increased the firing rate of dopamine (DA) neurons both in the zona compacta of the substantia nigra and the ventral tegmentum. Under these conditions buspirone was equipotent with haloperidol. When applied iontophoretically buspirone had little effect, *per se*, but it blocked the DA or GABA-induced inhibition of DA cells. Classical antipsychotic drugs affect only the DA elicited responses. Buspirone also produced a dose-dependent increase in rat plasma prolactin levels (the minimal effective dose being approximately 0.5 mg/kg) and blocked the inhibitory effect of DA on prolactin secretion.

In contrast to the neuroleptics, buspirone did not induce catalepsy in doses up to 200 mg/kg, and did not increase the density of ^{3}H-spiroperidol binding sites upon chronic administration.

Neurochemical studies revealed that buspirone was essentially devoid of *in vitro* interactions at the benzodiazepeine/GABA receptor complex. Specifically, buspirone lacked affinity either for ^{3}H-benzodiazepine binding sites (IC_{50} >100 μM) or for GABA binding sites.

Furthermore, while in the presence of GABA or GABA agonists the affinity of the receptors increased for benzodiazepines, buspirone had no significant effect on either receptor affinity or density in concentrations ranging from 0.1 to 100 μM. The binding of a high affinity chloride ionophore radioligand also remained unaffected. However, under *in vitro* conditions, buspirone did enhance the binding of ^{3}H-diazepam in the cortex and cerebellum, a finding which is

opposite to that seen with most, but not all, benzodiazepines.

Buspirone, like the neuroleptics, inhibited the binding of ^{3}H-spiperone and ^{3}H-n-propylapomorphine (IC_{50} approximately 150 nM). Furthermore, the drug increased the rate of DA synthesis and turnover as demonstrated by a significant increase in the levels of striatal HVA and DOPAC. The latter effects were brought about by doses of 5 and 10 mg/kg buspirone. However, buspirone was a weak inhibitor of dopamine-stimulated adenylate cyclase. Buspirone was shown to have weak or no affinity *in vitro* to cortical 5-HT_1, and 5-HT_2 receptors although it did bind to hippocampal 5-HT_1, receptors (IC_{50} approximately 95 nM). More recently, buspirone has been identified as a 5-HT_{1A} receptor agonist. This interaction results in attenuated serotonergic neurotransmission brought about by decreased serotonin synthesis and release.

Buspirone was inactive at all other receptor sites studied, which included the α_1, α_2 and ß-adrenergic, A_1 and A_2 adenosine, muscarinic cholinergic, H_1 and H_2 histamine, opiate, glycine and glutamate receptors. Buspirone did not inhibit the neuronal reuptake of DA, NE and 5-HT. The chronic administration of buspirone did not modify receptor density at α_1, α_2, ß or 5HT_2 binding sites.

Based upon animal experiments the abuse potential and dependence liability of buspirone seems to be minimal. The drug was not self-administered in monkeys trained to self-administer cocaine; it did not block convulsions precipitated in mice by the withdrawal of chronically administered phenobarbital and caused no weight loss when stopped abruptly after repeated

administration. Furthermore, buspirone did not share discriminative stimulus properties with either oxazepam or pentobarbital.

Buspirone is extensively metabolized and less than 1% of an oral dose is excreted unchanged. The major metabolites of buspirone are 5-hydroxybuspirone, which is pharmacologically essentially inactive, and its further oxidized derivatives and 1-(2-pyrimidinyl)-piperazine (1-PP) which is obtained by oxidative dealkylation. 1-PP is an active metabolite; it has anticonflict activity, and in contrast to buspirone, is highly effective at central α_2-adrenoceptors (IC_{50} approximately 25 nM) but virtually inactive at other binding sites.

TOXICOLOGY

Acute Toxicity:

Species	Sex	Route	LD_{50} (95% Confidence Interval) mg/kg
Rat (Adult) Rat (Adult)	Males Males/Females	Oral Oral	265 (174-404) 196 (152-252)
Rat (Newborn)	Males/Females	Oral	415 (332-520)
Mouse	Males	Oral	655 (529-811)
Dog	Males/Females	Oral	586 (371-925)
Monkey	Males/Females	Oral	356 (302-420)
Rat (Adult)	Males/Females	Intra-peritoneal	136 (122-152)
Mouse	Males	Intra-peritoneal	164 (145-185)
Mouse	Males	Intravenous	73.3 (66.6-80.6)
Monkey	Males/Females	Intravenous	54.3 (47.6-61.9)
Dog	Females	Intravenous Infusion	125.3 (lowest lethal dose-infused at 80 mg/kg/h - 30.8 mL/h)

Signs of toxicity in all species included hypoactivity, salivation, tremors, ataxia, opisthotonus and clonic convulsions.

In the dog intravenous infusion test, 10 mg/kg/h for a total of 59 mg/kg produced an increase in blood pressure and a slight increase in the ST segment of the EKG. At 40 and 80 mg/kg/h, an increase in heart rate and T-wave amplitude was also observed. The animals at the higher doses died following convulsions.

Subacute Toxicity:

Dog:

In a two week dose ranging study, one male and one female dog per group were administered 73, 110 or 146 mg/kg buspirone orally immediately after feeding. Both high dose dogs died on day 5 following convulsions. The mid dose male died on day 11, probably due to acute gastric dilatation. Reddening of gastric mucosa was observed at necropsy in all three dogs that died.

Rat:

In a three month study, groups of 15 males and 15 females were administered 0, 50, 100 and 200 mg/kg/day of buspirone in the diet. Reduced weight gain was observed in all treated groups as well as slight but significant decreases in erythrocyte and serum protein values. A significant decrease in serum glucose levels was seen in the mid and high dose groups.

Monkey:

In a three month study, 2 males and 2 female per group received 0, 37.5, 75 and 150 mg/kg of buspirone by gavage 3 hours after feeding. Hypoactivity, tremors and salivation were observed in all treated groups. Other observations included catatonia in the mid dose group, ataxia in the

high dose group, and general incoordination in which the monkey would be in almost constant movement and unable to walk or grasp objects normally, in both mid and high dose groups.

Chronic Toxicity:

Rat:

In a 2 year study, buspirone was administered in the diet to groups of 70 male and 70 female rats at doses of 0, 48, 80 and 160 mg/kg/day. Food consumption and weight gain were reduced in the treated animals in a dose-related manner. Rapid respiration, tremors and tachycardia were observed in all treated groups, hypersensitivity in mid and high dose groups, and hunched, thin appearance and red or mucoid nasal discharge in the high dose group. Findings at necropsy included a dose-related incidence of pulmonary histiocytosis and some decreases in organ weights.

Mouse:

A 78-week study was conducted with groups of 65 male and 65 female mice, who received buspirone 0, 50, 100 and 200 mg/kg/day in the diet.

Food intake was not affected, but decreased weight gain was observed in all treated groups. Necropsy findings included an increased incidence of amyloid deposition in some tissues of the high dose animals, particularly in the renal, gastrointestinal and testicular tissues of males. An increased incidence of focal testicular atrophy was also observed in high dose males.

Monkey:

Groups of 4 male and 4 female Rhesus monkeys were given buspirone orally at doses of 0, 35, 62 and 110 mg/kg/day. After 23 days, buspirone doses were reduced to 25 mg/kg once daily, 25 mg/kg twice daily and 50 mg/kg twice daily, respectively for the remainder of the one year study.

One male in the mid dose and 4 males and 2 females in the high dose group died relatively early during the study (2 more died at the end). Slight to marked weight loss was seen in some of the monkeys that died. Prior to dose reduction, sedation was moderate at the low dose, and marked at the mid and high dose. For the remainder of the study, slight to marked dose related sedation as well as intention tremors were observed in all treated groups. Mid and high dose monkeys also showed lack of responsiveness to stimuli and partial to total anorexia. Chewing on the cage or on the wrist was noted in high dose monkeys.

Some monkeys at the mid and high dose levels showed lower hemoglobin, hematocrit and alkaline phosphatase levels than controls, while in the high dose group, SGOT, and SGPT levels were slightly higher and serum cholesterol levels lower than in controls.

At necropsy, some changes in organ weights were observed, especially in the high dose group. Gross evidence of gastrointestinal irritation was found in all 7 monkeys that died during the study. A bloody diarrhea had been noted in 4 of the animals prior to death. One male monkey died at the end of the study, with gross evidence of pericarditis and pleuritis. No distinct or consistent drug related histopathologic changes were found in this study.

Carcinogenicity:

One two-year combined carcinogenicity and toxicity study has been carried out in rats (see Chronic Toxicity). No evidence was found of a drug-related effect on mortality, incidence of palpable tissue masses, gross pathologic findings, organ weights or microscopically detected neoplasms.

Reproduction and Teratology:

The potential effect of buspirone on the fertility and reproductive performance of the rat was studied by mating treated female rats with non-treated males and vice versa. Groups of rats were administered 9, 18 or 36 mg/kg/day of buspirone for 14 days prior to mating and continuing until 21 days post partum. The only finding was that the pup weights were statistically lower at birth and during weaning of the offspring from both the male and female rats treated with 9, 18 or 36 mg/kg/day of buspirone. This was due to a more pronounced effect on pup weight in the litters with greater numbers of pups. The survival index for pups from highest dose female treated rats was reduced. The lactation index was reduced at 36 mg/kg dose level and the survival index was reduced when both parents were treated with buspirone.

There were no skeletal or visceral abnormalities or other finding indicating a teratogenic or embryotoxic effect in rats or rabbits treated during embryogenesis with doses of 9, 18 or 36 mg/kg/day. Administration of buspirone to the pregnant rat at 36 mg/kg/day or less during the last third of pregnancy and throughout the 3 week post-natal period revealed no evidence of any adverse effect on fetal development, birth weights, post-natal growth or survival.

REFERENCES

1. Balster RL, Woolverton WL. Intravenous buspirone self-administration in rhesus monkeys. J Clin Psychiatry 1982; 43: 34-7.

2. Bourin M, Auget JL, Colombel MC, Larousse C. Effects of single oral doses of bromazepam, buspirone and clobazam on performance tasks and memory. Neuropsychobiology 1989; 22: 141-5.

3. Cohn JB, Bowden CL, Fisher JG, Rodos JJ. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 1986; 80(Suppl. 3B): 10-6.

4. Cohn JB, Wilcox CS. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. J Clin Psychiatry 1986; 47: 409-12.

5. Cohn JB, Wilcox CS, Meltzer HY. Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. Am J Med 1986; 80(Suppl 3B): 36-40.

6. Cole JO, Hech Orzack M, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982; 43: 69-74.

7. Dourish CT, Hutson PH, Curzon G. Putative anxiolytics 8-OH-DPAT, buspirone and TVX Q 7821 are agonists at 5-HT_{1A} autoreceptors in the raphé nuclei. TIPS 1986; 7: 212-4.

8. Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982; 43: 103-7.

9. Gammans RE, Bullen WW, Briner L, LaBudde JA. The effects of buspirone binding to the binding of digoxin, dilantin, propranolol, and warfarin to human plasma. Fed Proc 1985; 44: 1123.

10. Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med 1986; 80(Suppl. 3B): 41-51.

11. Gammans RE, Mayol RF, LaBudde JA, Casten GP. Metabolic fate of $^{14}C/^{15}N$-buspirone in man. Fed Proc 1982; 41: 1335.

12. Garattini S, Caccia S, Mennini T. Notes on buspirone's mechanisms of action. J Clin Psychiatry 1982; 43: 19-22.

13. Geller I, Hartmann RJ. Effects of buspirone on operant behavior of laboratory rats and cynomolgus monkeys. J Clin Psychiatry 1982, 43: 25-32.

14. Glaser T, Traber J. Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol 1983; 88: 137-8.

15. Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114-29.

16. Goldberg HL. Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy. Pharmacotherapy 1984; 4: 315-24.

17. Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. J Clin Psychiatry 1982; 43: 87-91.

18. Griffith JD, Jasinski DR, Casten GP, McKinney GR. Investigation of the abuse liability of buspirone in alcohol-dependent patients. Am J Med 1986; 80(Suppl 3B): 30-5.

19. Mayol RF, Adamson DS, Gammans RE, LaBudde JA. Pharmacokinetics and disposition of ^{14}C-buspirone HCl after intravenous and oral dosing in man. Clin Pharmacol Ther 1985; 37: 210.

20. Meltzer HY, Flemming R, Robertson A. The effect of buspirone on prolactin and growth hormone secretion in man. Arch Gen Psychiatry 1983; 40: 1099-1102.

21. Meltzer HY, Simonovic M, Fang VS, Gudelsky GA. Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover. Psychopharmacology 1982; 78: 49-53.

22. Mennini T, Gobbi M, Ponzio F, Garattini S. Neurochemical effects of buspirone in rat hippocampus: evidence for selective activation of 5-HT neurons. Arch Int Pharmacodyn 1986; 279: 40-9.

23. MolitorJA, Gammans RE, Carroll CM, LaBudde JA. Effect of buspirone on mixed function oxidase activity in rats. Fed Pro 1985; 44: 1257.

24. Napoliello MJ, Domantay AG. Buspirone: a worldwide update. Br J Psychiatry 1991; 159(Suppl. 12): 40-4.

25. Pecknold JC, Familamiri P, Chang H, et al. Buspirone: anxiolytic? Prog Neuro-Psychopharmacol Biol Psychiatr 1985; 9: 639-42.

26. Riblet LA, Eison AS, Taylor DP, et al. Neuropharmacology of buspirone. Psychopathology 1984; 17: 69-78.

27. Riblet LA, Taylor DP, Eison MS, Stanton HC. Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 1982; 43: 11-6.

28. Skolnick P, Paul SM, Weissman BA. Preclinical pharmacology of buspirone hydrochloride. Pharmacotherapy 1984, 4: 308-14.

29. Wheatley D. Buspirone: multicenter efficacy study. J Clin Psychiatr 1982; 43: 92-4.

30. United States Food and Drug Administration Summary Basis for Approval documents for Buspar® (buspirone hydrochloride) NDA 18-731, Sept. 21, 1988.

31. AHFS Drug Information 1992, American Society of Hospital Pharmacists Inc., Bethesda, MD, U.S.A., 1355-61.

32. Physicians' Desk Reference, 46th Edition, 1992, Oradell, N.J. U.S.A., pp. 1401-3.

33. Product Monograph for Buspar® (Buspirone Hydrochloride). Bristol Laboratories of Canada, Division of Bristol-Myers Squibb Canada Inc., Montreal, Canada. November 12, 1993.

34. Two-Way Single Dose Fasting Bioavailability Study of Buspirone (10 mg Tablet) in Normal Healthy Male Volunteers. Completed August 1995.

35. Two-Way Single Dose Fed Bioavailability Study of Buspirone 10 mg Tablets Administered as 4 X 10 mg Tablet in Normal Healthy Male Volunteers. Completed December 1995.